ArticleTransfusion2025
Genetics by genetic algorithm: Defining an ideal platelet donor population to support patients with HLA-mediated alloimmune refractoriness.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Demand for human leukocyte antigen or human platelet antigen-selected platelets: An observational study at Canadian Blood Services.Transfusion · 2026Observational
- Genetics by genetic algorithm: Defining an ideal platelet donor population to support patients with HLA-mediated alloimmune refractoriness.Transfusion · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundImmune factors underlie approximately 20% of patients exhibiting platelet transfusion refractoriness (PTR). PTR can be mitigated by supplying HLA-A and B compatible platelets to these patients. Since 2019, Canadian Blood Services has managed a program to provide compatible platelets to alloimmunized patients. This study evaluates donor pool size and ethnic diversity options to serve Canada's population. STUDY DESIGN AND
methodsWe adapted simulation-based stem cell matching methods by generating simulated patients and matching them to existing and simulated donors using a Python algorithm. Recruitment scenarios included census-aligned, single-group, and meta-heuristic-optimized distributions to enhance match rates and equity.
resultsMore typed donors increase match rates, but rates vary significantly by ethnicity. Non-Black patients achieved 95% coverage with 13,000-18,000 new donors, whereas Black patients required ~55,000 new donors. Single-ethnicity recruitment improved the targeted group's rate but reduced overall match rates and disadvantaged other populations. A Pareto-optimal donor mix-augmenting Black, Hispanic, Asian Pacific Islander, and Native American/First Nations donors while modestly reducing White typing-preserved or improved rates but yielded only modest gains for Black patients. A balanced strategy further prioritizing Black and Hispanic donors with slight reductions in White, Asian, and Native American/First Nations typing achieved improvements for the Black population with minimal losses for others. DISCUSSION: While Pareto-optimal allocation enhances overall efficiency, targeted trade-offs, focusing on underrepresented groups, are essential to correct persistent disparities and achieve equitable HLA-matched platelet availability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.